Leidos Holdings Inc Share Price Nyse
Equities
US78390X1019
IT Services & Consulting
End-of-day quote
Other stock markets
|
||
- USD | - |
03/06 | Wells Fargo Adjusts Price Target on Leidos Holdings to $168 From $158 | MT |
23/05 | TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing | MT |
Sales 2024 * | 1.62TCr 1,35500Cr | Sales 2025 * | 1.69TCr 1,41100Cr | Capitalization | 1.95TCr 1,63200Cr |
---|---|---|---|---|---|
Net income 2024 * | 104.9Cr 8.76TCr | Net income 2025 * | 108.8Cr 9.09TCr | EV / Sales 2024 * | 1.42 x |
Net Debt 2024 * | 355.24Cr 30TCr | Net Debt 2025 * | 335.14Cr 28TCr | EV / Sales 2025 * | 1.35 x |
P/E ratio 2024 * |
19
x | P/E ratio 2025 * |
17.8
x | Employees | - |
Yield 2024 * |
1.08% | Yield 2025 * |
1.15% | Free-Float | 98.93% |
Latest transcript on Leidos Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Bell
CEO | Chief Executive Officer | 63 | 28/23/28 |
Christopher Cage
DFI | Director of Finance/CFO | 52 | 01/99/01 |
Michele Brown
CMP | Compliance Officer | - | 01/08/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry Kraemer
BRD | Director/Board Member | 69 | 01/97/01 |
Bob Shapard
CHM | Chairman | 68 | 27/13/27 |
Surya Mohapatra
BRD | Director/Board Member | 74 | 16/16/16 |
1st Jan change | Capi. | |
---|---|---|
-17.91% | 18TCr | |
-2.07% | 16TCr | |
+1.38% | 15TCr | |
+5.38% | 9.99TCr | |
+12.12% | 8.17TCr | |
+19.62% | 7.47TCr | |
-9.67% | 7TCr | |
-31.16% | 4.58TCr | |
-11.09% | 4.28TCr |